Innocan Pharma to list on NYSE American

Executive Summary

• Innocan Pharma Corp. anticipates listing its common shares on the NYSE American on or around January 30, 2026, subject to regulatory approval and compliance with exchange rules.
• The company is conducting a concurrent offering of its securities in connection with the anticipated NYSE listing, with additional details to be provided via SEC and SEDAR+ filings.
• Trading on the OTCQB will terminate on or about January 29, 2026, while shares will continue to trade on the Canadian Securities Exchange under the symbol INNO.

Key Details

• Anticipated NYSE American Listing Date: On or around January 30, 2026.
• Listing Conditions: Subject to approval of the listing application and continued compliance with NYSE American rules.
• Concurrent Offering: Innocan is conducting a concurrent offering of its securities; specific terms, price, and proceeds are pending and will be disclosed in future SEC and SEDAR+ filings.
• OTCQB Trading Termination: Common shares will continue to trade on OTC Markets' OTCQB until the close of the market on or about January 29, 2026.
• Shareholder Action: Stockholders do not need to take any action prior to the listing.
• Canadian Listing Status: Common shares will continue to trade on the Canadian Securities Exchange under the symbol INNO.

Notable Quotes

• None provided in the text.